Navigation Links
Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening

NOIDA, India, Jan. 21 /PRNewswire/ -- Jubilant Organosys Ltd, headquartered in Noida near New Delhi, announced today that its subsidiary Jubilant Biosys Ltd., based in Bangalore, has developed a next generation screening solution, Legend NGSS(TM), that will further enable the process of high throughput screening, accelerating global drug discovery. The software to be launched in the US and Europe initially, allows scientists to capture, store, and analyze Oracle 9i/10g based screening data with greater flexibility, accuracy and speed.

Legend NGSS(TM) allows users to create rich visualization and interactive analysis reports, including dose-response curves and scatter plot heat maps. The novel tool allows flexible and interactive mother to daughter plate mapping from any plate reader. This generates best-fit kinetic and time course assays, without internal IT intervention, complete management of compound and targeted libraries, and optimized on-the fly curve-fitting techniques.

"This novel screening tool for scientific, pharmaceutical and biotech communities around the world can enhance the productivity of pharmaceutical and biotech research," said Christoph Pittius, PhD, Vice President, Global Business Development, Jubilant Biosys.

"This innovative product demonstrates Jubilant's strategy to develop and provide enabling technologies to accelerate the process of Drug Discovery and Development," he added further.

Legend NGSS(TM) has been developed in collaboration with a leading global pharmaceutical company. It is available worldwide on a subscription basis, which includes comprehensive software support and training. The product has generated substantial interest and response during prelaunch activities from global pharmaceutical companies involved in drug discovery.

About Jubilant Biosys

Jubilant Biosys Ltd. headquartered in Bangalore (, is a subsidiary of India-based Jubilant Organosys Ltd. It provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has 125,000 sq. ft. state-of-the-art facility in Bangalore, India. The center houses more than 500 scientists specializing in Bioinformatics, in vitro, in vivo biology, HTS, medicinal chemistry, structural biology, pharmacology, molecular modeling, information technology, and other scientific disciplines. The company has expanded relationships with the global pharmaceutical industry across the drug discovery and development value chain.

Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, the largest custom research and manufacturing services (CRAMS) and drug discovery and development services company out of India. The Company's consolidated sales in FY '07-08 stood at over US$ 600 million.

SOURCE Jubilant Biosys
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jubilant and BioLeap Announce New Partnership in Drug Discovery
2. SemBioSys announces senior management changes
3. Prosolia and Indigo BioSystems Come Together to Create FireFly(TM) Data Conversion Software for Mass Spectrometers
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research
6. SemBioSys begins phase I/II trial of insulin produced in plant seeds
7. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
8. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
9. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
10. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
11. SemBioSys announces second quarter 2008 financial and operational results
Post Your Comments:
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North Carolina, ... Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture Network (HTVN) ... their fourth annual Conference where founders, investors, innovative practitioners and collaborators are invited ... competition showcasing early stage digital health and med tech companies. , This day-long ...
(Date:10/5/2017)... Philadelphia, PA (PRWEB) , ... October 05, 2017 , ... ... of the newest frontiers in human health. Gut Love: You Are My Future, the ... offers an artist’s perspective as it explores the human condition through the lens of ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):